Adcendo

📢 Are you attending #BIOEurope2024?   Our CEO, Michael Pehl, is joining the '"Two for the Price of One!" The ADC arena' panel discussion on 5th of November at 14:00 CET!   Michael will be joining fellow antibody-drug-conjugate industry leaders and experts in the field to provide his thoughts on the current #ADC landscape, and more.   Get in touch to arrange a meeting with the Adcendo team in Stockholm - we hope to see you there for an insightful panel discussion!   Find out more about Adcendo's transformative year in this announcement. https://lnkd.in/dPY4-Fxh   #BIOEurope #biotech #cancer #oncology #lifesciences

🎉 We are pleased to welcome to our team Daniela Pontieri, who is joining us as our new Research Scientist, with a focus on target expression, histology and image analysis. 👩🔬   Daniela will contribute to key pre-clinical research activities helping further shape our understanding of the biology of target cancer indications across our pipeline programs. A warm Welcome to Adcendo, Daniela!   We look forward to the exciting journey ahead towards improved treatment options for cancer. 🚀🔬 

Adcendo has had a very eventful 2024 so far.   In May, we announced a second extension to our series A, welcoming a seventh investor to our international investor syndicate, and taking total funds raised to 98m EUR. https://lnkd.in/exnRSsFP In August, we announced a successful in-licensing deal with Multitude Therapeutics, adding an exciting, first-in-class ADC asset to our growing pipeline. https://lnkd.in/d2uTpb6j   In September, we secured room to grow and moved into our brand-new offices and laboratories at Symbion Frederiksberg.   Here in October, we received the news that our IND application for the program upon which the Company was founded, had received FDA clearance to commence clinical trials. https://lnkd.in/d3ZzYxRx   We are actively expanding, and we have ambitious hopes for the Company and for the future of cancer treatment.   🎉 Therefore, we are very pleased to find ourselves nominated for EY Entrepreneur Of The Year 2024. 🎉 Congratulations to all of the nominees, and thank you to the nominating committee and partners for considering Adcendo for this prestigious award.   #EOYDanmark #entrepreneurship #growth  

👉 CLOSED FOR APPLICATIONS 👈 As we head into the clinical development stage, Adcendo is seeking a Research Senior Scientist to join our preclinical team with the main responsibility for exploring the mode of action of novel ADC targets and evaluating combination treatment opportunities in vitro and in vivo. This position requires a strong scientific background and in-depth understanding of molecular cancer research, cancer biology and oncology. We offer an international work environment that fosters innovation and rewards excellence. This is a fantastic opportunity to contribute to the future of cancer treatment as part of a forward-thinking company! Find more details about the job and how to apply: https://lnkd.in/dH6vSuvH #Adcendo #ADCs #cancer #careeropportunity #jobopening #scientist #Copenhagen

📢 PRESS RELEASE! 📢 Adcendo are very pleased to announce that we have received US FDA IND clearance to commence a Phase I/II Trial of our uPARAP-targeting ADC, ADCE-D01, in patients with metastatic and/or unresectable soft tissue sarcoma (#STS).   The trial, named ADCElerate-01, is a first-in-human Phase I/II trial designed to evaluate the safety, pharmacokinetics, and preliminary efficacy of ADCE-D01, a first-in-class antibody-drug conjugate (#ADC). The uPARAP receptor is an endocytic receptor highly overexpressed in mesenchymal cancers including multiple STS subtypes.   This marks yet another highlight here in 2024, which has been a transformative year for the company in terms of growth and development, as we commence our transition into becoming a clinical-stage biotech company.   📰 Learn more about Adcendo and our next steps as we prepare for #clinicaltrial recruitment in the US and EU for testing ADCE-D01 as a monotherapy in patients, in the press release linked in the comments below!   #biotech #oncology #softtissuesarcoma #lifesciences   Read the full press release here: https://lnkd.in/d3ZzYxRx

Welcome Jørgen! We are growing our toxicology department and are excited to present our newest member of the team! Please join us in welcoming Jørgen Schützsack as our new Director, Toxicology. His expertise will undoubtedly contribute to our success as we continue to advance our pipeline of novel antibody-drug conjugates (ADCs) designed to treat cancer patients with unmet medical needs. Welcome to Adcendo, Jørgen! We look forward to the exciting journey ahead as we make strides towards better treatment of cancer. 🚀🔬 Follow our Company LinkedIn page for news and information about upcoming open positions. #Adcendo #NewHire #CancerResearch #ADCs #Toxicology #WeAreGrowing

Meet the Adcendo team at #ESMO2024 in Barcelona! 

Grand Opening! What an amazing new change! Last week we celebrated moving into our new headquarters, featuring fantastic offices and laboratories 🚀🔬. This move marks a significant milestone in our rapid growth journey.   Our new space is designed to foster innovation and collaboration, and it immediately felt like being in the exact right place. We can’t wait to see the groundbreaking work that will emerge from these premises.   Follow our page for exciting updates and news about open positions. Join us on this thrilling journey! #Adcendo #NewPremises #WeAreGrowing

We’re thrilled to welcome Jie (Will) HU to Adcendo as new Director of Business Development!   Will has a solid background in business and corporate development within the Biotech industry. We are confident his expertise will be instrumental in advancing our mission to develop and deliver innovative ADC solutions for cancer patients.   Welcome to Adcendo, Will! We look forwarding to an exciting journey ahead as we make significant strides towards better cancer treatments. 🚀🔬   Follow our Company LinkedIn page for news and updates about upcoming open positions.   #Adcendo #BusinessDevelopment #Oncology #Welcome #TeamGrowth #NewBeginnings

Running Into The Clinic!   What a great day for the Adcendo team of runners at the DHL relay last week.   Our team is continuously growing on our path towards clinical testing of our innovative ADC solutions for cancer patients, so follow our page for news about open positions. #Adcendo #GreatTeam #Oncology